Corcept Therapeutics Inc (CORT)

02:19 AM

What analysts say about Corcept Therapeutics Incorporated stockExceptional financial outcomes - Autocar Professional

02:19 AM

01:29 AM

Is Corcept Therapeutics Incorporated stock overhyped or has real potentialFree Market Dynamics Reports - jammulinksnews.com

01:29 AM

Jul 24, 2025

Corcept (CORT) Advances Ovarian Cancer Therapy with FDA Filing for Relacorilant - Yahoo Finance

Jul 24, 2025

Jul 24, 2025

Should I buy Corcept Therapeutics Incorporated stock before earningsTriple-digit returns - jammulinksnews.com

Jul 24, 2025

Jul 24, 2025

What drives Corcept Therapeutics Incorporated stock priceFree Predictions - Autocar Professional

Jul 24, 2025

Jul 24, 2025

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call - Business Wire

Jul 24, 2025

Jul 23, 2025

Corcept Advances Cancer Drug as Analysts Back Strong Growth Prospects - Yahoo Finance

Jul 23, 2025

Jul 22, 2025

Is Corcept Therapeutics Incorporated a good long term investmentFree Wealth Management Insights - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

Corcept Therapeutics Incorporated Stock Analysis and ForecastConsistently outstanding ROI - Autocar Professional

Jul 21, 2025

Jul 21, 2025

Corcept Therapeutics (NASDAQ:CORT): A High-Conviction Buy in the Biopharma Sector Amid EPS Growth and Strategic Momentum - AInvest

Jul 21, 2025

Jul 21, 2025

Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Is Well Worth Watching - Yahoo Finance

Jul 21, 2025

Jul 21, 2025

Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years - Benzinga

Jul 21, 2025

Jul 20, 2025

Corcept Therapeutics Incorporated (NASDAQ:CORT) is largely controlled by institutional shareholders who own 70% of the company - simplywall.st

Jul 20, 2025

Jul 18, 2025

agilon health, LifeStance Health Group, The Pennant Group, Corcept, and Amphastar Pharmaceuticals Shares Plummet, What You Need To Know - TradingView

Jul 18, 2025

Jul 17, 2025

FDA approval sought of relacorilant for platinum-resistant ovarian cancer - Rare Cancer News

Jul 17, 2025

Jul 16, 2025

M&T Bank Corp Sells 3,530 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World

Jul 16, 2025

Jul 15, 2025

Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. Sells 2,200 Shares of Stock - Defense World

Jul 15, 2025

Jul 15, 2025

Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer - Yahoo Finance

Jul 15, 2025

Jul 15, 2025

Why Corcept Therapeutics Incorporated stock attracts strong analyst attentionShort Term Profit Focus - Newser

Jul 15, 2025

Jul 15, 2025

How rare disease-focused Corcept Therapeutics expanded into cancerSan Francisco Business Times - The Business Journals

Jul 15, 2025

Jul 14, 2025

Corcept seeks FDA approval for ovarian cancer treatment (CORT) - Seeking Alpha

Jul 14, 2025

Jul 14, 2025

Corcept Therapeutics' Relacorilant NDA Submission: A Breakthrough in Ovarian Cancer and a Strategic Pivot to Oncology - AInvest

Jul 14, 2025

Jul 14, 2025

Corcept Therapeutics Submits New Drug Application to FDA - TipRanks

Jul 14, 2025

Jul 14, 2025

Corcept Therapeutics Files New Drug Application for Treatment of Platinum-Resistant Ovarian Cancer - MarketScreener

Jul 14, 2025

Jul 14, 2025

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire

Jul 14, 2025

Jul 11, 2025

Corcept Therapeutics’ Korlym Shows Glucose Control, Weight Reduction in Hypercortisolism, Type 2 Diabetes Patients - MSN

Jul 11, 2025

Jul 11, 2025

Piper Sandler reiterates Overweight rating on Corcept Therapeutics stock By Investing.com - Investing.com Canada

Jul 11, 2025

Jul 06, 2025

Corcept Therapeutics: A New Standard of Care in Ovarian Cancer Emerges - AInvest

Jul 06, 2025

Jul 06, 2025

Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA Trial - MSN

Jul 06, 2025

Jul 05, 2025

13 Best Pharma Stocks to Buy According to Wall Street Analysts - Insider Monkey

Jul 05, 2025

Jul 04, 2025

A New Dawn in Diabetes Treatment: Corcept Therapeutics' Korlym and the Untapped $2.8 Billion Opportunity - AInvest

Jul 04, 2025

Jul 03, 2025

Corcept therapeutics officer Guyer sells $7350 in shares By Investing.com - Investing.com Canada

Jul 03, 2025

Jul 03, 2025

Corcept therapeutics officer Guyer sells $7350 in shares - Investing.com

Jul 03, 2025

Jul 02, 2025

Adrenocortical Carcinoma Pipeline Therapeutics Gets a Boost With 20+ Active Pharma Players | DelveInsight - The Globe and Mail

Jul 02, 2025

Jul 02, 2025

10 Best NASDAQ Growth Stocks to Buy for the Next 3 Years - Insider Monkey

Jul 02, 2025

Jun 30, 2025

Corcept Therapeutics (NasdaqCM:CORT) Dropped From Russell 2000 and Growth Index - Yahoo Finance

Jun 30, 2025

Jun 29, 2025

Corcept Therapeutics Incorporated(NasdaqCM: CORT) added to Russell Midcap Index - MarketScreener

Jun 29, 2025

Jun 24, 2025

Corcept ALS Drug Shows Significant Survival Benefit Despite Missed Primary Endpoint - Yahoo Finance

Jun 24, 2025

Jun 23, 2025

Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85 - Business Wire

Jun 23, 2025

Jun 19, 2025

Insider Decision: Gary Charles Robb Offloads $225K Worth Of Corcept Therapeutics Stock - Nasdaq

Jun 19, 2025

Jun 16, 2025

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much TodayCorcept Therapeutics (NASDAQ:CORT) - Benzinga

Jun 16, 2025

Jun 16, 2025

Corcept reports annual meeting outcomes By Investing.com - Investing.com Canada

Jun 16, 2025

Jun 16, 2025

Corcept May 2025 slides: Revenue target of $900-950M amid pipeline advances - Investing.com Canada

Jun 16, 2025

Jun 13, 2025

Corcept Therapeutics director Daniel Swisher sells $155k in stock By Investing.com - Investing.com UK

Jun 13, 2025

Jun 13, 2025

Corcept Therapeutics director Daniel Swisher sells $155k in stock - Investing.com Australia

Jun 13, 2025